Understanding how AMPK affects heart damage from a common cancer drug
Official title: Deciphering the Role of AMPK in Doxorubicin Cardiotoxicity
Funded at New York Inst of Technology · NIH-10580326 · Data updated 2026-11-12
This study is looking at how a protein called AMPK might help protect the heart from damage caused by a common cancer drug, doxorubicin, while still allowing the drug to work effectively against cancer, so that patients can have safer treatment options.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Inst of Technology NIH-funded |
| Lab location | 1 site (Old Westbury, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $428,400 |
| NIH project number | 1R15HL163707-01A1 |
| Project ID | NIH-10580326 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are being treated with doxorubicin and are at risk of heart complications.
✕Less likely to help
Patients who are not receiving doxorubicin or those with pre-existing severe heart conditions may not benefit from this research.
What this research studies
This research investigates the role of AMP-activated protein kinase (AMPK) in reducing heart damage caused by doxorubicin, a widely used cancer treatment. The study aims to identify whether activating AMPK can protect the heart without reducing the drug's effectiveness against cancer. Researchers will use both cell-based studies and animal models to explore how different AMPK isoforms influence doxorubicin's cardiotoxic effects. By understanding these mechanisms, the research seeks to find ways to improve the safety of cancer treatments for patients.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments that minimize heart damage for patients receiving doxorubicin.
How similar studies have gone: Previous studies have shown promise in using AMPK activation to mitigate drug-induced cardiotoxicity, suggesting potential for success in this approach.
Where this research is happening
-
New York Inst of Technology
Old Westbury, United States Active
Researchers
- Principal investigator: Liang, Qiangrong — New York Inst of Technology
- Study coordinator: Liang, Qiangrong
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
High-throughput 3D human heart tissue to screen drug safety
A Johns Hopkins team is creating a high-throughput, 3D human heart tissue model to test drug safety on human heart cells.
-
Precision imaging of heart damage from cancer treatment using metabolic MRI biomarkers
Researchers will use advanced MRI to find early metabolic signs of heart injury in cancer patients treated with common drugs, so doctors can protect the heart earlier.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.